GSK, Medicago Forge Agreement to Develop Novel Adjuvanted COVID-19 Vaccine

GlaxoSmithKline is providing its pandemic adjuvant technology to another company to bolster the chances of developing a vaccine against COVID-19.

This morning, the pharma giant announced a partnership with Canada’s Medicago to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system.